Corcept Therapeutics Soars After FDA Clears Relacorilant for Specific Platinum-Resistant Ovarian Cancers
Shares of Corcept Therapeutics climbed about 40% after the U.S. Food and Drug Administration granted approval for relacorilant (Lifyorli) used in combination with nab-paclitaxel to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The decision, completed 2.5 months ahead of the target date, is su…